BioSpace News Archive

Homology Medicines, Inc., a genetic medicines company, announced financial results for the third quarter ended September 30, 2021, and highlighted recent accomplishments.

The US Food & Drug Administration (FDA) approved BESREMi® (active pharmaceutical ingredient Ropeginterferon alfa-2b), confirming the efficacy and safety for treatment of Polycythaemia Vera, a rare blood cancer disease.

Cognition Therapeutics, Inc. announced the closing of an additional 565,217 shares of its common stock following the exercise in full of the underwriters’ over-allotment option in connection with Cognition’s initial public offering.

VBL Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

Leuven, BE, Boston, MA, US – 15 November 2021 – 07.00 AM CET – Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces the first patient has been dosed in Part B of its two-part, Phase 2 study evaluating multiple injections of THR-149 for the treatment of DME.

The protein detection and qualification market has been anticipated to grow at a significant speed in the forthcoming years.

The life science microscopy devices market is expected to witness stable growth during the forecast period of 2016-2024.

The global healthcare contract research outsourcing market is rising with increasing complex regulatory process & growing regulatory burden.

The rising prevalence of cerebrovascular disease and growing population of geriatrics who are more prone to heart diseases, the demand in the market for blood flow measurement devices is swiftly incrementing.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, reported financial results and provided a business update for the third quarter ended September 30, 2021.